



# Effect of COVID 19 Affecting Geriatric Patients

**Vishwa S. Padole, Ravi P. Kalsait, Ranjit Ambad, Prakash Kute**

Nagpur College of Pharmacy, Wanadongri, Hingna Road, Nagpur-441110, Maharashtra, India.

Datta Meghe Medical College, Shalinitai Meghe Hospital and Research center, Nagpur-441110, Maharashtra, India.

Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe), Wardha-442001, Maharashtra, India.

## ABSTRACT

**Introduction:** In December 2019, an upheaval of serious intense respiratory condition coronavirus 2 (SARS-CoV-2) diseases happens in Wuhan, Hubei Province, China spread across the country and glob. On February 12, 2020, WHO authoritatively name the illness brought about by the novel coronavirus as Coronavirus Disease 2019 (COVID-19).

**Discussion:** Geriatric are at high danger of COVID-19 contamination due to lessening invulnerability and a few partners with comorbidities like diabetes, hypertension incessant kidney ailment, ceaseless obstructive aspiratory malady. The mortality in geriatric patients with COVID – 19 is at raised hazard.

**Conclusion:** This survey means to sum up early discoveries on the study of disease transmission, clinical highlights, conclusion, the executives, and anticipation of COVID-19 in geriatric public.

**Key Words:** COVID-19, Geriatric, SARS-CoV-2, WHO, Viral

## INTRODUCTION

Viral contaminations are the most incessant irresistible ailments and are regular triggers for establishing significant wellbeing and financial damages. In late December 2019, a previously named novel coronavirus (2019-nCoV) right now named as a coronavirus (COVID-19) rose out of Wuhan, China, brought about a difficult flare-ups in numerous locales in China and growing all-inclusive. Human diseases with coronavirus COVID-19 have raised incredible general wellbeing fear globally.<sup>1</sup>

Its clinical attributes were fundamentally the same as those of viral pneumonia. After investigation of respiratory examples, the specialists at the Prevention Research Centers (PRC) Centers for Disease Control pronounced that pneumonia, later known as novel coronavirus pneumonia was brought about by a novel coronavirus. The World Health Organization (WHO) formally named the illness 'COVID-19'. The International Committees on Taxonomy of Viruses named the infection 'extreme intense respiratory disorder coronavirus 2 (SARS-CoV-2). Assignment of a conventional name for the novel coronavirus and the infec-

tion it caused is helpful for correspondence in clinical and logical research.<sup>2</sup>

Crown Virus Disease 2019 (COVID-19) is an RNA infection, with an average crown-like appearance under an electron magnifying lens because of the nearness of glycoprotein spikes on its envelope.<sup>3</sup> It isn't the first occasion when that a coronavirus causing a pestilence has been a huge worldwide wellbeing danger: in November 2019, an episode of coronaviruses (CoVs) with the severe intense respiratory disorder (SARS)- CoV began in the Chinese territory of Guangdong and once more, in September 2012 the Middle East respiratory condition (MERS)- Co V appeared.<sup>4</sup> There are four genera of CoVs: (I) - coronavirus (alpha CoV), (II) - coronavirus (beta CoV) most likely present in bats and rodents, while (III) – coronavirus (delta CoV), and (IV) - coronavirus (gamma CoV) presumably speak to avian species. The infection has characteristic and zoonotic inception: two situations that can conceivably clarify the starting point of SARS-CoV2 are: (I) regular choice in a creature have before zoonotic exchange; and (ii) common choice in people following the zoonotic transfer.<sup>4,5</sup> Clinical highlights and hazard factors are profoundly factor, making the clinical seriousness go from

### Corresponding Author:

**Vishwa S. Padole**, Nagpur College of Pharmacy, Wanadongri, Hingna Road, Nagpur-441110, Maharashtra, India.

ISSN: 2231-2196 (Print)

ISSN: 0975-5241 (Online)

Received: 18.06.2020

Revised: 22.07.2020

Accepted: 26.08.2020

Published: 08.09.2020

asymptomatic to fatal.<sup>6</sup> Comprehension of COVID-19 is ongoing. This survey means to sum up early discoveries on the study of disease transmission, clinical highlights, determination, the executives, and avoidance of COVID-19 in geriatric population.<sup>7</sup>

### COVID 19 IN GERIATRIC

Because of physiologic changes of maturing, diminished invulnerable capacity, and multi-morbidity, more established grown-ups are at fundamentally expanded hazard from COVID-19. Geriatrics is more powerless to the contamination itself and is bound to experience the ill effects of the serious type of COVID-19 illness and to have difficulties. Maturing may likewise entangle analysis, as geriatrics with respiratory infections frequently present atypically. The middle length from side effect beginning to death is 11.5 days in people >70 years versus 14 days in more youthful persons.<sup>8</sup>

An epidemiological examination report announced that geriatric individuals are generally at risk to SARS-CoV-2 (middle age at death 75 years), and the vast majority of the patients who passed on had comorbidities or a past filled with the medical procedure before admission.<sup>9</sup> Zhong et al., discovered that, in light of the clinical highlights of 1099 patients with COVID-19, the middle hatching time frame was 3 days (run 0–24 days), and the middle time from side effect beginning to death was 14 days.<sup>9,10</sup> For SARS-CoV disease, the middle illness was 4 days, the normal stretch from side effect beginning to emergency clinic confirmation was 3.8 days, and the normal span from medical clinic admission to death was 17.4 days.<sup>11</sup> The middle incubation time frame for COVID-19 is shorter than that for SARS and MERS. Nonetheless, the most extreme latency of SARS-CoV-2 right now watched is as high as 24 days, which may expand the danger of infection transmission. Also, individuals matured 70 years had a shorter middle stretch (11.5 days) from manifestation beginning to death contrasted and patients matured 70 years < (20 days), exhibiting that malady movement is quicker in geriatric individuals contrasted and more youthful people.<sup>9</sup> In that capacity, our emphasis ought to be on geriatric individuals who may be at risk against SARS-CoV-2.<sup>12</sup>

The infection that causes COVID-19 contaminates individuals everything being equal. In any case, proof to date proposes that two gatherings of individuals are at a higher danger of getting extreme COVID-19 ailment. These are geriatric individuals (that is individuals more than 60 years of age); and those with hidden ailments, (for example, cardiovascular malady, diabetes, ceaseless respiratory infection, and malignant growth). The danger of serious malady increases bit by bit with age begins from around 40 years. It's significant that grown-ups in this age go secure themselves and thus ensure others that might be at risk.

Numerous investigations progressively certain that demise rate increments with children under 9 years old appear to be generally unaffected, either with no or gentle manifestations or none have kicked the bucket due to COVID-19 disease. While individuals beyond eighty years old and those with interminable maladies are the most defenceless. For those cross 80, around 14.80% of those tainted dies. The casualty rate begins to increment for those more than 50 years old. Those under 50 years who are contaminated have a passing pace of 0.40%, while for those 50-59 years it's 1.3%. For those 60-69 years it's 3.60%, for 70 to 79-year-olds it's 8.00% and for those more than 80 years old, it is 14.8%.<sup>13-15</sup>

Since most incessant renal patients are older as an outcome of physiologic decrease of renal capacity and higher defenselessness to renal maladies, the COVID-19 is a pertinent issue in ceaseless renal patients for its expanded danger of difficulties and mortality. Moreover, the utilization of some antiviral and immunosuppressive treatments to battle COVID-19 disease is confused by kidney harm with intense kidney injury. The age and the constant renal pathology together are most likely a hazard factor for COVID-19 for the immunosuppressive status.<sup>16</sup>

A portion of the reasons geriatrics are incredibly affected by COVID-19 incorporate the physiological changes related with maturing diminished safe capacity and multi-morbidity which open more seasoned grown-ups to be more vulnerable to the contamination itself and make them bound to experience the ill effects of COVID-19 ailment and more genuine complications.<sup>17</sup>

These people show a lot higher defenselessness to the sickness and poor clinical guess, and therefore, lower possibility of endurance. Curiously, the comorbidities have to mature as a typical factor and have been depicted lately as age-related infections. An ongoing report revealed assessments of the age-separated case casualty rate and demonstrated it to be lower in those under 60 years of age (1.4% [0.4–3.5]) contrasted with subjects who were 60 years or more seasoned (4.5% [1.8–11.1]).<sup>18</sup> In any case, the explanation the geriatric and those with previous conditions show a higher hazard for COVID-19 is at present obscure.

An extra element that portrays the serious instances of COVID-19 is the raised degrees of irritation that can bargain lung tissue honesty and capacity, prompting pneumonia. Surprisingly, aggregated and depleted T cells discharge especially supportive of incendiary cytokines, for example, IFN and TNF. These cytokines can contribute, alongside the inborn invulnerable framework, to the second rate favourable to provocative foundation saw in the geriatric,<sup>19</sup> which may intensify COVID-19 results and clarify the raised degrees of inflammation. It is likewise conceivable that age-related clonal hematopoiesis may add to the expanded irritation because of hematopoietic undifferentiated cell myeloid age

predisposition of supportive of fiery macrophages and pole cells, and decrease of lymphoid differentiation.<sup>20</sup> Moreover, diminished T-cell ability to appropriately actuate counteracting agent emitting cells to additionally evoke successful safe reactions might be compromised.<sup>21</sup> During maturing, the thymus gets atrophic and is step by step supplanted by fibrotic tissue.<sup>22</sup> These outcomes in a decreased number, or even total revocation, of leaving credulous T cells.<sup>23</sup> On the side of the significance of thymus involution, ongoing examinations show that the age-defined disease pace of COVID-19 connects with involution of the thymus.<sup>24</sup> Together, every one of these highlights may bring about the diminished capacity of more seasoned individuals to battle viral contaminations, prompting age-related aggravation and higher defenselessness of the lung to the COVID-19-delivered damage.<sup>25</sup>

## MORTALITY RATE

The mortality of the SARS-CoV-2 pandemic in geriatrics has been striking. As per the joint WHO-China reality discovering crucial, by and large Code Of Federal Regulations (CFR) of 17.3% in January diminished to .7% in February, though the CFR in grown-ups more seasoned than age 80 had expanded to 21.9%.<sup>26</sup> Another investigation of 72,314 cases showed a general CFR of 2.3%, yet a CFR of 8% in patients matured 70 to 79 years and 14.5% in patients more seasoned than 80.<sup>27</sup> A report on 355 patients with SARS-CoV-2 found that patients who passed on had a normal period of 79.5 years.<sup>28</sup> Another report on 4,226 cases in the United States demonstrated a CFR under 1% in patients more youthful than age 54 however a CFR of 3% to 11% in patients matured 65 to 84 and 10% to 27% in patients more seasoned than age 85.

Over 80% of passings among grown-up patients happen in those more seasoned than 65. Most of the lethal cases to date have included more established grown-ups and patients with comorbidities.<sup>27,29</sup> Many geriatrics in the United States have cardiovascular disease (17%), diabetes (26.8%), hypertension (63.1%), COPD (23.7%), and CKD (38%).<sup>30-34</sup> An investigation by the joint WHO-China reality discovering crucial that patients more seasoned than age 60 and those with comorbidities had the most elevated hazard for extreme infection and demise. The CFR in patients without comorbidities was 1.4%, though the CFR was 13.2% for patients with cardiovascular malady, 9.2% for patients with diabetes, 8.4% for patients with hypertension, 8% for patients with a constant respiratory infection, and 7.6% for patients with cancer.<sup>26</sup> One investigation on 46 deadly instances of SARS-CoV-2, in which 84% of patients were more established than age 60, found that diabetes is likely connected with expanded mortality.<sup>34</sup> Another examination on basically sick more established patients with SARS-CoV-2 found that 86% of patients had comorbid conditions, for example, CKD, congestive cardiovascular breakdown, Chronic Obstructive Pulmonary

Disease (COPD), and diabetes.<sup>35</sup> This probability of having various comorbidities places geriatrics at considerably more danger of expanded mortality from SARS-CoV-2.<sup>36</sup>

It has for some time been perceived inside Geriatric Medicine that more seasoned individuals with any disease may introduce atypically. Probably the commonest atypical introductions of foundational ailment are incoherence, utilitarian decay and fall since intense sickness prompt decompensating of prior ailments. For our situation, notwithstanding the gastrointestinal indications, we saw a mellow wooziness, practical decrease and an example of electrolyte unsettling influences predictable with Syndrome of Inappropriate Anti-Diuretic Hormone. It is as of now obscure if more established grown-ups with COVID-19 present distinctively to more youthful patients and our patient was more than 20 years more established than the normal age of the patient companion from Hubei province.<sup>37</sup> To date, most emergency of expected instances of COVID-19 has been founded on the nearness of respiratory side effects, however, older grown-ups are more averse to create fever or run of the mill manifestations with other respiratory viral ailments, for example, Influenza.<sup>38,39</sup> There is an earnest need to appropriately portray the range of clinical highlights in this patient group.<sup>40</sup>

## TREATMENT

The Taiwan CDC proclaimed hydroxychloroquine as a significant enemy of SARS-CoV-2 specialist on 26 March 2020. Of note, patients with retinopathy, insufficiency of glucose-6-phosphatase, QT bend prolongation in electrocardiograms, history of hypersensitivity to hydroxychloroquine are contraindicated for accepting hydroxychloroquine.<sup>41,42</sup>

The convergence of Chloroquine phosphate is kept up for an extended time, the plasma protein bind ingrate is about 55%, and the half-life is 2.5-10 days. The medication is metabolized by the liver, and 10%-15% of the medication is discharged by the kidney as the first. Geriatric patients with hindered kidney capacity might be a more serious hazard for harmful responses to the medication. Geriatric patients are bound to experience the ill effects of diminished renal capacity, diminished digestion of medications, and debilitated excretory capacity. Along these lines, the medication leftover portion in patients taking Chloroquine phosphate for 7-9 successive days may reach or even surpass the deadly dose.<sup>43</sup> According to ebb and flow reports, the populace is commonly defenceless to SARS-CoV-2 and geriatric individuals with basic sicknesses are bound to create extreme ailment. Heart failure is the most severe adverse response of Chloroquine phosphate. Geriatric patients who have been prescribed Chloroquine phosphate for treatment of COVID-19 must have an ordinary electrocardiogram before administering the drug. Chloroquine phosphate is restricted in blend with drugs that cause Q-T prolongation, for example, quinolones and macrolides. Simultaneously, the electrolyte



level (potassium, sodium, and chlorine), blood glucose, and liver and kidney elements of patients ought to be clear as should be expected. Geriatric patients ought not to be treated with at least three antiviral medications, including Chloroquine phosphate.<sup>44</sup>

The main investigation assessing impacts of Remdesivir in people randomized 681 patients contaminated with *ebola* virus to 4 distinctive treatment systems, out of which 175 patients got Remdesivir. Just 1 patient who got Remdesivir had hypotension and along these lines kicked the bucket because of heart arrest.<sup>45, 46</sup> The regular unfavourable occasion noted during thoughtful utilization of Remdesivir in patients with COVID-19 by Grein et al., incorporate rash, loose bowels, hypotension, irregular liver capacity and renal disability. Serious antagonistic impacts (intense kidney injury, septic shock, multi-organ disappointment) was noted in 23%, while 60% had, in any event, one unfavourable impact and 8% stopped because of the different reaction of remdesivir.<sup>47</sup> A close look on eGFR is essential while administrating Remdesivir, particularly in patients with known renal debilitation and suspension is required if eGFR tumbles to half from standard.<sup>48</sup> Four patients (8%) ended Remdesivir treatment mid: one in light of compounding of prior renal disappointment, one given various organ disappointment, and two due to high aminotransferases, incorporating one patient with a maculopapular rash.<sup>49</sup>

Human Anti-SARS-CoV-2 plasma varies from standard plasma just by ethicalness of the nearness of antibodies against SARS-CoV-2. Risk of bonding contagious contamination is low. Regularly referred to gauges are short of what one disease for every 2,000,000 gifts for HIV, hepatitis B and hepatitis C viruses.<sup>50</sup> There are additionally non-irresistible perils of bonding, for example, unfavourably susceptible bonding responses, bonding related circulatory overload (TACO), and bonding related intense injury.<sup>51</sup> While the danger of bonding related to the intense injury is commonly short of what one for each 5,000 bonded units, bonding related intense injury is of specific worry in extreme COVID-19 given likely preparing of the aspiratory endothelium. Notwithstanding, routine giver screening incorporates HLA immune response screening of female givers with a history of pregnancy to relieve the danger of bonding related intense injury.<sup>52</sup> Worth referencing, hazard factors for bonding related circulatory overload e.g. cardiorespiratory ailment, progressed age, renal debilitation and so on are shared by those in danger of COVID-19, underscoring the requirement for cautious consideration regarding liquid volume management.<sup>53</sup> Another concentrate in non - greatly bonded injury patients (<10 RBC units inside 12 hours of confirmation) comparably discovered expanded complexities with expanding volumes of plasma bonded. Patients bonded with more than 6 units of plasma had a 12-overlay increment in ARDS, six-fold increments

in multi-organ failure condition, and fourfold increments in pneumonia and sepsis.<sup>54,55</sup>

The geriatric patients with comorbidities especially cardiovascular dysfunction, renal debilitation during contamination with COVID 19 are at high danger of mortality. Prolongation of QT bend, ischemic coronary illness had been appeared to happen with the utilization of hydroxychloroquine, Remdesivir. Alert and close observing ought to be followed while recommending these medications in geriatric patients.

## CONCLUSION

Geriatric individuals are at a higher danger of COVID-19 contamination because of their diminished insusceptibility and body holds, just as numerous related comorbidities like diabetes, hypertension, interminable kidney sickness, nearness of malignant growth and ceaseless obstructive pneumonic malady. Additionally, the course of sickness will, in general, be more serious if there should be an occurrence of old bringing about higher mortality.

Be that as it may, COVID-19 transmission among the geriatric public can be decreased by taking a few estimates like:

- Stay at home. Abstain from meeting guests at home. In the case of the meeting is basic, keep up separation of one meter, washing hands and face at standard stretches with cleanser and water, sniffle and hack either into their elbow or into tissue paper/hanky. In the wake of hacking or sniffing, arrange the tissue paper/put the cloth for wash, guarantee legitimate nourishment through home prepared new hot suppers, hydrate now and again and take new squeezes to support insusceptibility. Do normal activities and perform reflection, take every day recommended medications routinely. They should converse with their relatives, family members, companions using video conferencing, and take help from relatives if necessary. Defer their elective medical procedures (assuming any) like waterfall medical procedure or all-out knee substitution. Clean the much of the time contacted surfaces with disinfectant routinely at home. Screen their wellbeing. On the off chance that they create fever, hack or potentially breathing trouble promptly contact the closest human services office and follow the clinical exhortation delivered.

## REFERENCES

1. Sultan A. M, Thamir Al-Khlaiwi, Adnan Mahmood Usmani, Anusha Sultan Meoc, David C. Klonoff, Thanh D. Hoang; Biological and epidemiological trends in the prevalence and mortality due to outbreaks of novel coronavirus COVID-19; JKSU – Science; doi.org/10.1016/j.ijantimicag.2020.105948
2. Wang L, Wang Y, Ye D, Liu Q; Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence; International Journal of Antimicrobial Agents; doi.org/10.1016/j.ijantimicag.2020.04.004

3. Perlman, S.; Netland, J. Coronaviruses post-SARS: Update on replication and pathogenesis. *Nat. Rev. Microbiol.* 2009; 7: 439–450.
4. Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *Lancet* 2020; 39(5): 565–574.
5. Yin, Y.; Wunderink, R.G. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology* 2018; 23: 130–137.
6. Phan, T. Novel coronavirus: From discovery to clinical diagnostics. *Infect. Genet. Evol.* 2020; 79: 1–2.
7. Gennaro F D, Pizzol D, Marotta C, Antunes, Racalbutto V, Veronese N and Smith L. Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review; *Int. J. Environ. Res. Public Health* 2020; 17: 2690; DOI:10.3390/ijerph17082690.
8. Malone ML, Hogan TM, Perry A, Biese K, Bonner A, Pagel P, Unroe KT, COVID-19 in Older Adults: Key Points for Emergency Department Providers; *JGEM*; March 18, 2020; 1 (4); 1–3
9. Wang W, Tang J, Wei F . an Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. *J Med Virol* 2020;92:441–7.
10. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of 2019 novel coronavirus infection in China. *N Engl J Med* 2020. 383 (18); 1708–1720.
11. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. *Lancet Infect Dis* 2009;9:291–300.
12. Wang L, Wang Y, Ye D, Liu Q; Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence ;*IJAA*;doi.org/10.1016/j.jksus.2020.04.004
13. Age, Sex, Existing Conditions of COVID-19 Cases and Deaths. <https://www.worldometers.info/coronavirus/coronavirusage-sex-demographics/>.
14. Vally H, The Conversion, La Trobe University. <https://theconversation.com/why-are-older-people-more-at-risk-of-coronavirus-133770>.
15. Hafeez A, Ahmad S, Siddiqui SA, Ahmad M, Mishra S; A Review of COVID-19 (Coronavirus Disease-2019) Diagnosis, Treatments and Prevention; *EJMO* 2020;4(2):116–125; DOI: 10.14744/ejmo.2020.90853
16. Coppolino, G, Presta P, Nicotera R, Placida G, Vita C, Carullo N, Andreucci M, Bolignano D, Castagna A, Ruotolo G; COVID-19 and renal disease in elderly patients; *Geriatric Care* 2020; 6:9029 doi:10.4081/gc.2020.9029
17. Henri H P. Kluge, WHO Regional Director for Europe; Statement – Older people are at highest risk from COVID-19, but all must act to prevent community spread; Copenhagen, 2 April 2020.
18. Verity, R. et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect. Dis.* 3099, 1–9 (2020).
19. Franceschi, C. et al. Inflamm-aging: An Evolutionary Perspective on Immunosenescence. *Ann. N. Y. Acad. Sci.* 2006; 908: 244–254.
20. Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis in human ageing and disease. *Science* 366, (2019).
21. Haynes, L. & Swain, S. L. Why Aging T Cells Fail: Implications for Vaccination. *Immunity*, 2006; 24: 663–666.
22. Flores, K. G., Li, J., Sempowski, G. D., Haynes, B. F. & Hale, L. P. Analysis of the human thymic perivascular space during ageing. *J. Clin. Invest.* 1999; 104: 1031– 1039.
23. Naylor, K. et al. The Influence of Age on T Cell Generation and TCR Diversity. *J. Immunol.* 2005; 174, 7446–7452.
24. Liu Z, Bing X ZaZhi X. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. 2020; 41: 145– 151.
25. Didac S, José PC, Aleksandr A. Zenin, Anastasia V. Shindyapina1, Maxim V. Gerashchenko1, Bohan Zhang1, Csaba Kerepesi1, Sun Hee Yim1, Peter O. Fedichev2, Vadim N. Gladyshev1; COVID-19 is an emergent disease of ageing;medRxiv preprint DOI: <https://doi.org/10.1101/2020.04.15.20060095>
26. WHO-China Joint Mission. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19).<https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf>. Accessed March 26, 2020.
27. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA.* 2020;323(13):1239–1242. <https://doi.org/10.1001/jama.2020.2648>
28. Italian COVID-19 Surveillance Group. Report sulle caratteristiche dei pazienti deceduti positivi a COVID-19 in Italia Il presente report è basato sui dati aggiornati al 17 Marzo 2020. [https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019\\_17\\_marzo-v2.pdf](https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_17_marzo-v2.pdf). Accessed March 26, 2020.
29. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054–1062. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
30. National Diabetes Statistics Report 2020. <https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf>. Accessed March 27, 2020.
31. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015–2016. *NCHS Data Brief No. 289*. Hyattsville, MD: National Center for Health Statistics; 2017.
32. CDC. Coronary Heart Disease, Myocardial Infarction, and Stroke—A Public Health Issue. <https://www.cdc.gov/aging/agingdata/docs/Coronary-Stroke-Brief-508.pdf>. Accessed March 26, 2020.
33. CDC. Chronic Obstructive Pulmonary Disease Among Adults—United States, 2011. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6146a2.htm>. Accessed March 26, 2020.
34. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497–506.
35. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. *JAMA.* 2020. <https://doi.org/10.1001/jama.2020.4326>
36. Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D, et al. ;COVID-19 and Older Adults: What We Know; *J. American Geriatrics Society* · April 2020 DOI: 10.1111/jgs.16472.
37. Pan, L.; Mu, M.; Yang, P.; Sun, Y.; Wang, R.; Yan, J.; Li, P.; Hu, B.; Wang, J.; Hu, C.; et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: A descriptive, cross-sectional, multicenter study. *Am. J. Gastroenterol.* 2020, in press
38. Falsey, A.R.; Baran, A.; Walsh, E.E. Should clinical case definitions of influenza in hospitalized older adults include fever? *Influenza Other Respir. Viruses* 2015, 9 (1), 23–29.
39. Andrew, M.K.; McElhaney, J.E.; McGeer, A.A.; Hachette, T.F.; Leblanc, J.; Webster, D.; Bowie, W.; Poirier, A.; Nichols, M.K.; McNeil, S.A.; et al. Influenza surveillance case definitions miss a substantial proportion of older adults hospitalized with labo-

- ratory-confirmed influenza: A report from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network. *Infect. Control Hosp. Epidemiol.* 2020, 9, 1–6.
40. Alistair J. Mackett 1 and Victoria L. Keevil; COVID-19 and Gastrointestinal Symptoms—A Case Report; *Geriatrics* 2020, 5, 31; DOI:10.3390/geriatrics5020031.
  41. Gautret P, Lagier J, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents* 2020 Mar 17. <https://doi.org/10.1016/j.ijantimicag.2020.105949>.
  42. Shio-Shin Jean, Ping-Ing Lee, Po-Ren Hsueh; Treatment options for COVID-19: The reality and challenges; *Journal of Microbiology, Immunology and Infection* (2020); <https://doi.org/10.1016/j.jmii.2020.03.034>.
  43. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends*. 2020;14(1):72–73.
  44. Xuelin Sun1 | Shaoqiang Li1,2 | Kexin Li3 | Xin Hu1; Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID-19); *Ageing medicine*; <https://doi.org/10.1002/agm2.12104>.
  45. Mulangu S, Dodd LE, Davey RT Jr., Tshiani Mbaya O, Proschan M, Mukadi D, et al Team PCS; A randomized, controlled trial of Ebola virus disease therapeutics; *N Engl J Med* 2019;381:2293–2303.
  46. Aggarwal G, Henry BM, Aggarwal S, and Bangalore S; Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019; *The American Journal of Cardiology*; <https://doi.org/10.1016/j.amjcard.2020.04.054>.
  47. Grein J, Ohmagari N, Shin D, et al. Compassionate use of Remdesivir for patients with severe Covid-19. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMoa2007016>. published online April 10.
  48. Singh A, \*, Akriti Singh, Ritu Singh c, p Misra A; Remdesivir in COVID-19: A critical review of pharmacology, preclinical and clinical studies; *Diabetes and Metabolic Syndrome: Clinical Research & Reviews*; <https://doi.org/10.1016/j.dsx.2020.05.018>.
  49. Grein J., Ohmagari, N. . Shin, D. Diaz, G. Asperges, E. Castagna, A. T. Feldt et al; Compassionate Use of Remdesivir for Patients with Severe Covid-19; *N Engl J Med* 2020;382:2327–36. DOI: 10.1056/NEJMoa2007016.
  50. Busch MP, Bloch EM, and Kleinman S. Prevention of transfusion-transmitted infections. *Blood* 2019;133(17):1854–64.
  51. Hendrickson JE, and Hillyer CD. Noninfectious serious hazards of transfusion. *Anesth Analg*. 2009;108(3):759–69.
  52. A.B. Standards for Blood Banks and Transfusion Services. Bethesda, MD: AABB; 2018.
  53. Bloch EM, Bailey JA, Aaron A.R. Tobian; Deployment of convalescent plasma for the prevention and treatment of COVID-19; *The journal of clinical investigation*; <https://doi.org/10.1172/JCI138745>.
  54. Inaba K, Branco BC, Rhee P, Blackburne LH, Holcomb JB, Teixeira PG, Shulman I, Nelson J, Demetriades D. Impact of plasma transfusion in trauma patients who do not require massive transfusion. *J Am Coll Surg* 2010;210: 957–65.
  55. Pandey S and Vyas G; Adverse effects of plasma transfusion\_3663 65.79; doi: 10.1111/j.1537-2995.2012.03663.x.